BIOCRYST PHARMACEUTICALS INC (BCRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 150M 300M 450M Q3 '21: 41M Q4 '21: 47.2M Q1 '22: 49.9M Q2 '22: 65.5M Q3 '22: 75.8M Q4 '22: 79.5M Q1 '23: 68.8M Q2 '23: 82.5M Q3 '23: 86.7M Q4 '23: 93.4M Q1 '24: 92.8M Q2 '24: 109.3M Q3 '24: 117.1M Q4 '24: 131.5M Q1 '25: 145.5M Q2 '25: 163.4M Q3 '25: 159.4M Q4 '25: 406.6M Q1 '26: 156.4M Q2 '26: 218.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 150M 300M 450M Q3 '21: 40.4M Q4 '21: 46.7M Q1 '22: 49.7M Q2 '22: 65.3M Q3 '22: 72.3M Q4 '22: 77.2M Q1 '23: 67.8M Q2 '23: 81.6M Q3 '23: 85.6M Q4 '23: 91.8M Q1 '24: 91.5M Q2 '24: 107.6M Q3 '24: 113.9M Q4 '24: 125.4M Q1 '25: 141M Q2 '25: 160.6M Q3 '25: 157.2M Q4 '25: 397M Q1 '26: 151M Q2 '26: 214.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-750M -500M -250M 0 250M 500M 750M Q3 '21: -44.6M Q4 '21: -52.2M Q1 '22: -50M Q2 '22: -34.7M Q3 '22: -17.4M Q4 '22: -46.3M Q1 '23: -28.4M Q2 '23: -20.7M Q3 '23: -11.9M Q4 '23: -42.7M Q1 '24: -14.5M Q2 '24: 8.8M Q3 '24: 7.7M Q4 '24: -4.5M Q1 '25: 21.2M Q2 '25: 29.8M Q3 '25: 29.6M Q4 '25: 260.4M Q1 '26: -701.6M Q2 '26: 98.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-750M -500M -250M 0 250M 500M 750M Q3 '21: -58.8M Q4 '21: -17.8M Q1 '22: -74.2M Q2 '22: -58.9M Q3 '22: -42.5M Q4 '22: -71.5M Q1 '23: -53.3M Q2 '23: -75.3M Q3 '23: -36.1M Q4 '23: -61.7M Q1 '24: -35.4M Q2 '24: -12.7M Q3 '24: -14M Q4 '24: -26.8M Q1 '25: 32K Q2 '25: 5.1M Q3 '25: 12.9M Q4 '25: 245.8M Q1 '26: -721.8M Q2 '26: 78.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 3.5M 7M 10.5M Q3 '21: 591K Q4 '21: 418K Q1 '22: 236K Q2 '22: 246K Q3 '22: 3.5M Q4 '22: 2.4M Q1 '23: 931K Q2 '23: 894K Q3 '23: 1.1M Q4 '23: 1.6M Q1 '24: 1.3M Q2 '24: 1.7M Q3 '24: 3.2M Q4 '24: 6.1M Q1 '25: 4.6M Q2 '25: 2.8M Q3 '25: 2.2M Q4 '25: 9.5M Q1 '26: 5.4M Q2 '26: 3.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-100M 0 100M 200M 300M Q3 '21: -23.3M Q4 '21: -32.5M Q1 '22: -77.8M Q2 '22: -27.8M Q3 '22: -32.4M Q4 '22: -23.8M Q1 '23: -47.5M Q2 '23: -18.8M Q3 '23: -19.9M Q4 '23: -8.9M Q1 '24: -53.7M Q2 '24: -1.4M Q3 '24: 8.2M Q4 '24: -5.2M Q1 '25: -27.5M Q2 '25: 41.3M Q3 '25: 41.6M Q4 '25: 292M Q1 '26: -61.8M Q2 '26: 104.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-100M 0 100M 200M 300M Q3 '21: -23.6M Q4 '21: -33.6M Q1 '22: -78.2M Q2 '22: -28M Q3 '22: -32.6M Q4 '22: -24.4M Q1 '23: -47.7M Q2 '23: -19.3M Q3 '23: -20.9M Q4 '23: -9.5M Q1 '24: -53.9M Q2 '24: -1.5M Q3 '24: 8.2M Q4 '24: -5.9M Q1 '25: -27.7M Q2 '25: 41.1M Q3 '25: 40.3M Q4 '25: 291.2M Q1 '26: -62.2M Q2 '26: 104.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 100M 200M 300M Q1 '20: 154.2M Q2 '20: 161.6K Q3 '20: 176.5K Q1 '21: 177.3M Q2 '21: 178.1M Q3 '21: 179.1M Q1 '22: 184.9M Q2 '22: 185.6M Q3 '22: 186.2M Q1 '23: 188.5M Q2 '23: 189.1M Q3 '23: 189.6M Q1 '24: 206.1M Q2 '24: 206.4M Q3 '24: 206.9M Q1 '25: 215.3M Q2 '25: 219.9M Q3 '25: 219.9M Q1 '26: 242.3M Q2 '26: 265.2M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.10 -1.40 -0.70 0.00 0.70 1.40 2.10 Q3 '21: -1.27 Q4 '21: -1.03 Q1 '22: -1.07 Q2 '22: -1.15 Q3 '22: -1.05 Q4 '22: -1.33 Q1 '23: -1.21 Q2 '23: -1.29 Q3 '23: -1.25 Q4 '23: -1.18 Q1 '24: -1.07 Q2 '24: -0.73 Q3 '24: -0.61 Q4 '24: -0.43 Q1 '25: -0.26 Q2 '25: -0.18 Q3 '25: -0.05 Q4 '25: 1.21 Q1 '26: -1.77 Q2 '26: -1.49 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.